[
  {
    "ts": null,
    "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
    "summary": "Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda. The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity. Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data compiled by LSEG, up 7% from year-ago levels and the highest year-to-date total since 2023.",
    "url": "https://finnhub.io/api/news?id=aa71f0be0003cfe114ac843836c74786c4f8fe821089df0c9499277cb095e9cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752083138,
      "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
      "id": 135855739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda. The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity. Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data compiled by LSEG, up 7% from year-ago levels and the highest year-to-date total since 2023.",
      "url": "https://finnhub.io/api/news?id=aa71f0be0003cfe114ac843836c74786c4f8fe821089df0c9499277cb095e9cc"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street waves off Trump's 200% pharma tariff threat",
    "summary": "President Trump threatened as much as 200% tariffs on pharma Tuesday. By Wednesday morning, Wall Street had ignored the threat.",
    "url": "https://finnhub.io/api/news?id=f696d5cb21c2f80d43981b6002d0e6a0abf371941220b1f8f1f952da059a4a90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752075698,
      "headline": "Wall Street waves off Trump's 200% pharma tariff threat",
      "id": 135835678,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "President Trump threatened as much as 200% tariffs on pharma Tuesday. By Wednesday morning, Wall Street had ignored the threat.",
      "url": "https://finnhub.io/api/news?id=f696d5cb21c2f80d43981b6002d0e6a0abf371941220b1f8f1f952da059a4a90"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?",
    "summary": "Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=63a0114138e254231028cc2e07689496e69ab3d29618e1179b17cde3fab9179d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752069608,
      "headline": "Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?",
      "id": 135835724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=63a0114138e254231028cc2e07689496e69ab3d29618e1179b17cde3fab9179d"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=b6fef3dc37dbaea012624e44ff52f35d4eaae1591639ce46e114923f6f6acdc8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752068403,
      "headline": "Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term",
      "id": 135835725,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=b6fef3dc37dbaea012624e44ff52f35d4eaae1591639ce46e114923f6f6acdc8"
    }
  },
  {
    "ts": null,
    "headline": "Merck Faces Multiple Challenges: Will It Steer Through Successfully?",
    "summary": "MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.",
    "url": "https://finnhub.io/api/news?id=3913d662aa4220ce980be59df562b1a9635337751fca0692b11b698b88d7d6f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067440,
      "headline": "Merck Faces Multiple Challenges: Will It Steer Through Successfully?",
      "id": 135835679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.",
      "url": "https://finnhub.io/api/news?id=3913d662aa4220ce980be59df562b1a9635337751fca0692b11b698b88d7d6f9"
    }
  },
  {
    "ts": null,
    "headline": "JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?",
    "summary": "JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.",
    "url": "https://finnhub.io/api/news?id=a86b9dbd8b7aabe2229ea6c55ec1bfc8413de7c088bef9cd2a32c486de83df64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752066660,
      "headline": "JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?",
      "id": 135835727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.",
      "url": "https://finnhub.io/api/news?id=a86b9dbd8b7aabe2229ea6c55ec1bfc8413de7c088bef9cd2a32c486de83df64"
    }
  },
  {
    "ts": null,
    "headline": "Mar Vista U.S. Quality Q2 2025 Commentary",
    "summary": "Mar Vistaâs U.S. Quality strategy returned +12.40% net-of-fees in the second quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=8b72ca1b995cffe84b95d3ca95d08f2f66b37a532c67c30078ee28488cb6f3b8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752065460,
      "headline": "Mar Vista U.S. Quality Q2 2025 Commentary",
      "id": 135835306,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193247029/image_2193247029.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Mar Vistaâs U.S. Quality strategy returned +12.40% net-of-fees in the second quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=8b72ca1b995cffe84b95d3ca95d08f2f66b37a532c67c30078ee28488cb6f3b8"
    }
  },
  {
    "ts": null,
    "headline": "SpaceX Just Made Elon Musk $20 Billion Richer",
    "summary": "SpaceX has a new valuation, according to Bloomberg.  The $50 billion increase makes Musk about $20 billion richer, as he is thought to hold some 40% of SpaceX stock.  Musk’s total stake in SpaceX is worth about $160 billion.",
    "url": "https://finnhub.io/api/news?id=382b6f155a8ef8627be80bed73dcff26ee00e5a3b011cdc33e1714ae86927e18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752064800,
      "headline": "SpaceX Just Made Elon Musk $20 Billion Richer",
      "id": 135835662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "SpaceX has a new valuation, according to Bloomberg.  The $50 billion increase makes Musk about $20 billion richer, as he is thought to hold some 40% of SpaceX stock.  Musk’s total stake in SpaceX is worth about $160 billion.",
      "url": "https://finnhub.io/api/news?id=382b6f155a8ef8627be80bed73dcff26ee00e5a3b011cdc33e1714ae86927e18"
    }
  },
  {
    "ts": null,
    "headline": "Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks",
    "summary": "GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.",
    "url": "https://finnhub.io/api/news?id=617e80dcec7cbb0d66dc74c27877563c0794436d0f689321e590d39f1cf7d4b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752063480,
      "headline": "Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks",
      "id": 135835729,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.",
      "url": "https://finnhub.io/api/news?id=617e80dcec7cbb0d66dc74c27877563c0794436d0f689321e590d39f1cf7d4b2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?",
    "summary": "Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?",
    "url": "https://finnhub.io/api/news?id=45959ee6f0a339f6fb470f3e9e440c05c2a1cad836f69e4f79bb96a8e0522c56",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752055365,
      "headline": "Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?",
      "id": 135834214,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=45959ee6f0a339f6fb470f3e9e440c05c2a1cad836f69e4f79bb96a8e0522c56"
    }
  },
  {
    "ts": null,
    "headline": "WTV: The Winning Active Value ETF",
    "summary": "WTV: The Winning Active Value ETF",
    "url": "https://finnhub.io/api/news?id=bafb7faf3cef6f09f515f58466f7179c704ba02b21b100603992f8cb7aedfd39",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752050189,
      "headline": "WTV: The Winning Active Value ETF",
      "id": 135833373,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=bafb7faf3cef6f09f515f58466f7179c704ba02b21b100603992f8cb7aedfd39"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Copper Retreats, Crude Oil Gains",
    "summary": "Wall Street Breakfast Podcast: Copper Retreats, Crude Oil Gains",
    "url": "https://finnhub.io/api/news?id=d13c0fd7bd9bea9d332dbd29920dcf60d2d9e801da166cb3231e75c76bfcabb5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752049080,
      "headline": "Wall Street Breakfast Podcast: Copper Retreats, Crude Oil Gains",
      "id": 135833163,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d13c0fd7bd9bea9d332dbd29920dcf60d2d9e801da166cb3231e75c76bfcabb5"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Applied to the European Medicines Agency to Expand AKEEGA Usage",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 3, Janssen-Cilag, a company of Johnson & Johnson (NYSE:JNJ), reported applying to the European Medicines Agency to expand the use of AKEEGA, a drug that combines niraparib and abiraterone acetate. The new application seeks approval for […]",
    "url": "https://finnhub.io/api/news?id=33cd9a4370648669c623104fbd53fa7a113a0b25c48f191b14d49b76cf6f5181",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752037411,
      "headline": "Johnson & Johnson (JNJ) Applied to the European Medicines Agency to Expand AKEEGA Usage",
      "id": 135829766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 3, Janssen-Cilag, a company of Johnson & Johnson (NYSE:JNJ), reported applying to the European Medicines Agency to expand the use of AKEEGA, a drug that combines niraparib and abiraterone acetate. The new application seeks approval for […]",
      "url": "https://finnhub.io/api/news?id=33cd9a4370648669c623104fbd53fa7a113a0b25c48f191b14d49b76cf6f5181"
    }
  }
]